Skip to content

Single-Ingredient Series · Evidence Review

An evidence-based review of beta-nicotinamide mononucleotide, NAD+ precursor supplementation, human outcomes, dosing, safety, and regulatory context.

Published: June 2026Sources: 22 verified primary referencesEvidence: Meta-analyses · RCTs · Mechanistic · Safety · Regulatory

Executive summary

What the evidence says

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to energy metabolism, DNA repair, and cellular longevity signaling. Human tissue concentrations of NAD+ decline by an estimated 50% between early adulthood and the sixth decade of life — a trajectory mechanistically linked to impaired mitochondrial function, reduced sirtuin activity, and hallmarks of biological aging. Beta-nicotinamide mononucleotide (β-NMN) is the direct precursor to NAD+ in the salvage biosynthesis pathway, the predominant route for NAD+ regeneration in human tissues. Oral βNMN supplementation consistently and reliably elevates circulating NAD+ and its metabolites across all nine published human randomized controlled trials, with a dose-dependent response confirmed from 250 mg to 900 mg per day. The strongest supported human evidence is NAD+ elevation itself — strong and highly consistent. Physical performance signals (gait speed, walking capacity) appear in three individual RCTs but are not confirmed in pooled meta-analyses and must be classified as preliminary. Insulin sensitivity improvement in prediabetic postmenopausal women is supported by one rigorous RCT published in Science but does not extend to the general population: two meta-analyses totaling over 850 participants found no significant effect on glycemic or lipid outcomes in healthy adults. Modest blood pressure reduction (diastolic) and improved sleep quality represent preliminary signals from smaller RCTs. The safety profile across all published trials is excellent, with no serious adverse events reported at doses up to 1,250 mg per day. Product: Beta-Nicotinamide Mononucleotide (NMN) 500 mg Capsules — Pacific Formulations Single-Ingredient Series.

What Is Beta-Nicotinamide Mononucleotide?

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide composed of three elements: a nicotinamide base (a form of vitamin B3), a ribose sugar, and a phosphate group. The "beta" designation

specifies its stereochemistry at the anomeric carbon of the ribose ring. β-NMN is the biologically active anomer — the form found in human cells, in natural food sources, and in every published clinical study. The alternative α-NMN anomer lacks biological relevance, and high-quality supplements specify the β form. β-NMN occurs in trace amounts in foods including edamame, broccoli, avocado, tomatoes, and raw beef. Dietary quantities, however, are in the low microgram range per gram of food — several orders of magnitude below the milligram doses studied in clinical trials — and degrade rapidly during cooking and storage. Supplementation is therefore the only practical means of achieving the blood NAD+ elevations documented in the human evidence base.

NAD+ and Why It Declines With Age

NAD+ (nicotinamide adenine dinucleotide) functions as a coenzyme in over 500 enzymatic reactions, including glycolysis, the citric acid cycle, oxidative phosphorylation, and fatty acid oxidation. Critically, it is the obligate substrate for two families of NAD+-consuming enzymes that regulate gene expression, DNA integrity, and metabolic homeostasis: the sirtuins (SIRT1–7) and poly(ADP-ribose) polymerases (PARPs). NAD+ tissue concentrations decline substantially with age — an estimated 50% from the third to sixth decade — driven by three converging mechanisms: decreased activity of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway; increased consumption by CD38, a NADase upregulated by aging-associated inflammation; and increased PARP1 activity driven by accumulating DNA damage.1,2 The resulting NAD+ insufficiency impairs sirtuin-mediated DNA repair, mitochondrial biogenesis, and metabolic regulation in multiple tissues simultaneously. β-NMN is the direct substrate product of NAMPT and the immediate NAD+ precursor in the salvage pathway — the step immediately upstream of NAD+ itself. Oral supplementation therefore provides the pathway's end intermediate, bypassing the rate-limiting NAMPT step.

Mechanism of Action

NAD+ Biosynthesis: Three Pathways

Human cells synthesize NAD+ via three routes: (1) the de novo pathway from dietary tryptophan via kynurenine intermediates; (2) the Preiss-Handler pathway from nicotinic acid (NA); and (3) the salvage pathway from nicotinamide (NAM) — recycled into NMN by NAMPT, then converted to NAD+ by NMN adenylyltransferases (NMNATs 1–3).2 The salvage pathway accounts for the majority of NAD+ regeneration in most human tissues. Oral β-NMN enters this pathway as the NAMPT product itself, bypassing the rate-limiting step entirely.

Intestinal Uptake of NMN

NMN is a charged nucleotide and was initially thought to require dephosphorylation to nicotinamide riboside (NR) prior to intestinal absorption. The discovery of the NMN-specific membrane transporter Slc12a8 — expressed in the small intestinal epithelium and multiple peripheral tissues — provides a direct cellular uptake mechanism for intact NMN.1 Human pharmacokinetic data show rapid appearance of NAD+ metabolites in blood within hours of oral NMN dosing, consistent with efficient gut absorption and rapid conversion to NAD+ and its downstream metabolites.4,16

Sirtuins: NAD+-Dependent Longevity Enzymes

Sirtuins (SIRT1–7) are NAD+-dependent deacylases that regulate gene expression, DNA repair, mitochondrial biogenesis, metabolic adaptation, and inflammatory signaling. Because sirtuin catalytic activity is directly coupled to NAD+ availability, declining NAD+ with aging progressively impairs the entire sirtuin family. SIRT1 (nuclear and cytoplasmic) governs gene expression programs and DNA damage response; SIRT3 (mitochondrial matrix) deacetylates and activates oxidative phosphorylation enzymes and antioxidant defenses. Restoring NAD+ via β-NMN supplementation reactivates sirtuin-mediated pathways in both compartments.1,3

PARP1 and DNA Damage Repair

PARP1 (poly ADP-ribose polymerase 1) is the primary cellular sensor of DNA strand breaks, consuming NAD+ as a substrate each time it detects and tags a break. As DNA damage accumulates with aging, PARP1 activity increases, creating a progressive drain on NAD+ that suppresses sirtuin function in a self-reinforcing feedback loop. β-NMN supplementation is hypothesized to sustain NAD+ supply sufficient to serve both PARP-mediated repair and sirtuin signaling simultaneously.1,2

Mitochondrial Function

NAD+ is the obligate electron carrier at mitochondrial complex I and complex III of the electron transport chain. SIRT3-mediated deacetylation, dependent on mitochondrial NAD+, regulates the activity of electron transport chain proteins, fatty acid oxidation enzymes, and antioxidant enzymes including MnSOD. Preclinical data demonstrate that chronic NMN supplementation in aging mice restores mitochondrial oxygen consumption, reduces oxidative stress markers, and reverses age-related gene expression changes in skeletal muscle — effects consistent with the NAD+/SIRT3 axis.3,17

eNAMPT and Inter-Tissue NAD+ Communication

Extracellular NAMPT (eNAMPT) is secreted by metabolically active tissues into circulation, where it synthesizes NMN extracellularly for uptake by peripheral tissues. The NAD World 3.0 framework proposes that hypothalamic eNAMPT/NMN signaling coordinates systemic NAD+ homeostasis across tissues, and that its progressive decline with aging is a primary driver of multi-tissue NAD+ insufficiency. 1

Supplemental β-NMN may partly substitute for declining eNAMPT-derived NMN supply in peripheral

tissues.

Evidence Review

NAD+ Elevation

STRONG

NAD+ elevation is the most consistently replicated finding in NMN research and the compound's strongest evidence base. All nine published human RCTs that measured blood NAD+ or NAD+ metabolites reported statistically significant increases in the NMN-treated groups. A 2026 PRISMAguided systematic review covering 33 human intervention studies (28 randomized) confirmed that oral NMN "consistently demonstrated biochemical target engagement" — characterizing this as the most robust finding across the entire NAD+ precursor literature.15 Lin et al. (2022) — Multicenter RCT, n=80, doses 300/600/900 mg/day, 60 days. GeroScience. All three NMN dose groups produced statistically significant increases in whole blood NAD+ vs. placebo at days 30 and 60 (p≤0.001 for all groups at both time points). The 600 mg and 900 mg groups showed the highest concentrations, with no significant difference between them. A clear dose-dependent relationship was established across the 300–900 mg range. NCT04823260.5

Okabe K et al. (2022) — Placebo-controlled RCT, n=30, 250 mg/day, 12 weeks. Frontiers in Nutrition. Blood NAD+ levels were significantly elevated at 4, 8, and 12 weeks in the NMN group vs. placebo (p<0.05 at all time points). Levels returned to near-baseline within 4 weeks of cessation (week 16 measurement), confirming supplement-dependence of the elevation. Nicotinic acid mononucleotide (NAMN) — a metabolite indicating activation of the broader NAD+ biosynthetic network — was also significantly elevated, suggesting a system-wide NAD+ metabolomic response rather than isolated pathway activation.4

Igarashi M et al. (2022) — Placebo-controlled RCT, n=20 healthy men ≥65 years, 250 mg/day, 12 weeks. npj Aging. Significant increases in whole blood NAD+, NMN, NAMN, and nicotinamide riboside (NAR) metabolites, confirmed by LC-MS/MS metabolomics. Increased metabolite diversity indicates that oral NMN activates multiple arms of the NAD+ biosynthetic network, not solely the direct salvage route.6

Katayoshi T et al. (2023) — Placebo-controlled RCT, n=36 healthy middle-aged adults (40–59 years), 250 mg/day, 12 weeks. Scientific Reports. Serum nicotinamide (NAM) — a downstream metabolite of NAD+ consumption, and therefore a proxy for elevated NAD+ turnover — was significantly higher in the NMN group vs. placebo (p=0.037). This metabolomic signature confirms NAD+ pathway activation even in populations where direct serum NAD+ detection falls below quantification limits at baseline.21

Physical Performance & Gait Speed

PRELIMINARYCONFLICTING VS. META-ANALYSES

Three individual RCTs report improvements in physical performance measures. Two subsequent meta-analyses pooling these and additional trials find no statistically significant pooled effect on skeletal muscle mass or function. Both findings must be reported.

Lin et al. (2022) — Multicenter RCT, n=80, 300/600/900 mg/day, 60 days. GeroScience. Sixminute walk test (6MWT) distance improved significantly across all three NMN dose groups vs. placebo (p<0.01). Blood biological age (assessed via biomarker composite) remained stable across all NMN groups over 60 days while increasing significantly in the placebo group (p<0.05). This is a notable secondary finding but was not a pre-registered primary endpoint and uses a proprietary assessment tool not independently validated. 5

Igarashi M et al. (2022) — RCT, healthy older men ≥65 years, 250 mg/day, 12 weeks. npj Aging. Gait speed showed a nominally significant improvement (p=0.033) and left grip strength improved (p=0.019). No significant changes in body composition or skeletal muscle mass by DXA scan. Authors describe these as nominal improvements requiring validation in larger, adequately powered studies.6

Morifuji M et al. (2024) — RCT, older adults, 250 mg/day, 12 weeks. GeroScience. Four-metre walking time was significantly shorter in the NMN group vs. placebo at 12 weeks (p<0.05). A significant negative correlation was observed between change in walking time and change in blood NAD+ metabolites (2PY, 4-PY), mechanistically linking the walking improvement to NAD+ pathway activity. The pre-specified primary outcome — a stepping test — showed no significant between-group difference at 4 or 12 weeks. UMIN000047871.7

Insulin Sensitivity

MODERATE — SPECIFIC POPULATION

Yoshino M et al. (2021) — Placebo-controlled RCT, postmenopausal women with prediabetes (overweight/obese), 250 mg/day NMN, 10 weeks. Science. The primary outcome — insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp, the clinical gold standard for insulin sensitivity — improved significantly in the NMN group (p<0.05). Mechanistic analysis confirmed increased phosphorylation of AKT and mTOR in skeletal muscle (downstream insulin signaling proteins), and transcriptomic analysis identified upregulation of platelet-derived growth factor receptor β and muscle remodeling gene programs. This is one of the most mechanistically rigorous RCTs in the NMN literature.8

Blood Pressure

PRELIMINARY

Systematic review and meta-analysis: NMN and blood pressure (2026) — 10 RCTs, n=349 participants, 11 intervention arms. Nutrients. PMID: 41901064. NMN supplementation produced a statistically significant reduction in diastolic blood pressure (DBP): weighted mean difference (WMD) = −2.15 mmHg (95% CI: −3.68 to −0.61, p<0.05). Systolic blood pressure (SBP) was not significantly reduced across the full sample; however, a pre-specified subgroup analysis restricted to participants aged ≥60 years showed a significant SBP reduction (WMD = −3.94 mmHg, 95% CI: −7.06 to −0.82). The authors characterize the overall body of evidence as "preliminary and suggestive" and note selective reporting concerns in some included studies. Larger, longer-term RCTs are needed before a robust conclusion can be drawn.10

Pencina MJ et al. (2023) — Placebo-controlled RCT, n=30 (overweight/obese adults ≥45 years), MIB-626 (pharmaceutical-grade β-NMN) 1,000 mg/day, 28 days. J Clin Endocrinol Metab. PMID: 36740954. Diastolic blood pressure decreased by 7.01 mmHg (p=0.034). Total cholesterol decreased by 26.89 mg/dL (p=0.004) and LDL-C by 18.73 mg/dL (p=0.007). Body weight decreased by 1.9 kg (p=0.008). No significant changes in muscle strength, aerobic capacity, or insulin sensitivity were observed. MIB-626 is a pharmaceutical-grade microcrystalline β-NMN formulation at a dose (1,000 mg/day) higher than most dietary supplement trials; this study is a small-sample, short-duration finding in a specific metabolic population and requires replication.9

The mechanistic basis for blood pressure effects is plausible: NAD+→SIRT1 activation promotes eNOS deacetylation and increased nitric oxide bioavailability, which supports vascular tone regulation. However, no form-specific, powered RCT for NMN and blood pressure as a primary outcome currently exists.

Sleep Quality

PRELIMINARY

Morifuji M et al. (2024) — RCT, older adults, 250 mg/day, 12 weeks. GeroScience. Pittsburgh Sleep Quality Index (PSQI) global score and the "Daytime dysfunction" subscale both improved significantly in the NMN group relative to placebo. The sleep disturbances subscale also trended toward improvement. Authors note the mechanistic correlation with elevated NAD+ metabolites as biologically plausible, consistent with NAD+'s known role in serotonin-to-melatonin conversion via arylalkylamine N-acetyltransferase (AANAT), a NAD+-linked enzyme in the circadian biosynthetic cascade.7

Kim M et al. (2022) — RCT, n=108 (104 completed) older Japanese adults, 250 mg/day NMN (morning vs. afternoon administration), 12 weeks. Nutrients. The afternoon-dosing NMN group (NMN_PM) showed the largest improvements in self-reported drowsiness (effect size d=0.64) and 5-times sitto-stand performance (d=0.72) compared with all other groups. Timing-dependent differences in outcomes may reflect circadian patterns of NAMPT activity and NAD+ biosynthesis, with afternoon supplementation better aligned to the NAD+ metabolic cycle in peripheral tissues.11

No RCT has designated sleep quality as a primary endpoint for NMN. Both sleep-relevant findings are secondary outcomes from trials designed primarily to evaluate physical function or safety. The signal is directionally consistent but requires a dedicated, adequately powered trial with validated polysomnographic or actigraphy endpoints before strong claims can be made.

Glycemic & Lipid Outcomes, General Population

NULL (NOT CLAIMED)

Systematic review and meta-analysis, 8 RCTs, n=342 middle-aged/older adults (2024). Current Diabetes Reports. PMID: 39531138. NMN supplementation at 250–2,000 mg/day for 14 days to 12 weeks produced no statistically significant benefit on fasting plasma glucose, fasting insulin, HbA1c, HOMA-IR, total cholesterol, LDL-C, HDL-C, or triglycerides in this predominantly non-diabetic population. Five of eight RCTs reported increased blood NAD+ levels — confirming biochemical target engagement — without corresponding metabolic benefit in healthy adults.12

Systematic review and meta-analysis, 12 RCTs, n=513 participants (2024). PMID: 39116016. 4,049 records screened. Confirmed significant NAD+ elevation across included RCTs. No statistically significant effect of NMN on fasting glucose, triglycerides, total cholesterol, LDL-C, or HDL-C vs. control. Risk-of-bias assessment: 7 studies with "some concerns," 5 with "high risk of bias" (RoB2). Authors noted that "exaggeration of the benefits of NMN supplementation may exist in the field" and called for larger, higherquality trials.13

Liver Function Markers

PRELIMINARY

A 2024 meta-analysis (PMID 39185644; 9 RCTs, n=412 middle-aged and elderly participants) found that NMN supplementation produced a modest but statistically significant reduction in serum ALT — a liver function biomarker — (SMD = −0.29 IU/L, 95% CI −0.55 to −0.03, p=0.028). The same analysis reported a gait speed improvement (SMD = 0.34 m/s, p=0.033) consistent with individual RCT findings in §3b.18 These are secondary pooled findings requiring dedicated clinical investigation; they are not primary study endpoints, and no liver health or hepatoprotective claim is made for this product.

Dosing & Usage

Evidence-Based Dosing Range

Outcome area NMN dose studied Duration Population
NAD+ elevation (minimum effective) 250 mg/day 4-12 weeks Healthy adults, all age groups
NAD+ elevation (dose-dependent range) 300-900 mg/day 60 days Healthy middle-aged adults
Physical function (gait/walking) 250-900 mg/day 8-12 weeks Older adults ≥60 years
Insulin sensitivity 250 mg/day 10 weeks Prediabetic postmenopausal women
Blood pressure (diastolic) 250-1,000 mg/day 4-12 weeks Mixed (10 RCTs, meta-analysis)
Sleep quality (secondary outcome) 250 mg/day 12 weeks Older adults

Pacific Formulations Product Dose

Pacific Formulations' Beta-NMN Capsules deliver 500 mg β-NMN per serving. This dose exceeds the minimum 250 mg/day shown to significantly elevate blood NAD+ in four independent RCTs,4,6,7,21 sits within the dose-dependent NAD+ elevation range of 300–900 mg/day established by Lin et al. (2022),5 and is consistent with the 500 mg twice-daily regimen (1,000 mg/day) used in the MIB-626 pharmacokinetic study, which produced a 3.7× increase above baseline in blood NAD+ AUC.22 The 500 mg per capsule dose therefore provides a meaningful, well-evidenced NAD+ precursor load in a singleserving format.

Timing

Most RCTs did not impose a specific dosing time. Kim et al. (2022) found that afternoon administration — compared with morning — was associated with larger effects on physical performance (5-STS effect size d=0.72) and self-reported drowsiness (d=0.64).11 This may reflect circadian variation in NAMPT activity and NAD+ turnover, with the salvage pathway most active in the mid-to-late day in peripheral tissues. Afternoon or early-evening dosing with food is a reasonable approach supported by this preliminary finding, though it is not a definitive recommendation based on current evidence.

Who May Benefit Most

The available evidence consistently points to a larger magnitude of benefit in individuals with lower baseline NAD+ status. This includes: adults over 50, who show the most pronounced age-related NAD+ decline;1 individuals who are overweight or have established metabolic dysfunction, in whom multiple NAD+-consuming pathways (CD38, PARP) may be more active;8,9 and those with reduced physical capacity, in whom the gait- and walking-related signals have been most apparent.6,7 NAD+ elevation in response to NMN is consistently demonstrated across age groups, but functional outcome benefits have been most evident in older adult populations.

Safety & Tolerability

Adverse Event Profile Across Clinical Trials

β-NMN demonstrates a consistently excellent safety and tolerability profile across all published human clinical trials. No serious adverse events (SAEs) attributable to NMN supplementation have been reported in any published trial. In the multicenter dose-escalation RCT by Lin et al. (2022), 9 total adverse events were recorded across all 80 participants: 6 occurred in the placebo group, 3 in the 300 mg NMN group, and zero in the 600 mg and 900 mg NMN groups — none attributed to NMN treatment.5

Highest-Dose Safety Study

Fukamizu Y et al. (2022) — Placebo-controlled RCT, n=31 healthy adults (20–65 years, both sexes), 1,250 mg/day β-NMN, 4 weeks. Scientific Reports. 12:13922. At 1,250 mg/day — the highest dose tested in any published human safety study — no significant changes were observed in hematological parameters, serum biochemistry (including liver enzymes, renal markers, and lipids), urinary markers, or body composition beyond normal physiological variation. Mutagenicity was negative (Ames assay, chromosome aberration, micronucleus assay). No vasodilatory flushing was observed (a side effect of nicotinic acid at doses above ~50 mg). No hepatotoxicity (in contrast to supraphysiological doses of nicotinamide). This study establishes a safety margin of 2.5× above the 500 mg Pacific Formulations product dose.14

First-in-Human Pharmacokinetic Dose Escalation

Irie J et al. (2019) — Single-arm open-label dose-escalation study, n=10 healthy Japanese men, single oral doses of 100/250/500 mg. Endocrine Journal. PMID: 31685720. No significant changes in vital signs, clinical symptoms, heart rate, blood pressure, or oxygen saturation at any dose. Minor fluctuations in serum bilirubin, creatinine, chloride, and glucose were observed but all remained within normal clinical ranges. NAD+ metabolites (N-methyl-2-pyridone-5-carboxamide and N-methyl-4-pyridone-5-carboxamide) appeared in plasma in a dose-dependent fashion, confirming absorption and metabolic conversion at all three doses including 500 mg single-dose.16

Safety Comparison With Other NAD+ Precursors

β-NMN's safety profile compares favorably with other NAD+ precursor compounds. Nicotinic acid (niacin) causes prostaglandin-mediated vasodilatory flushing at doses above ~50 mg — an effect absent with NMN in all published trials. Pharmacological doses of nicotinamide (>3 g/day) have been associated with hepatotoxicity and impairment of glucose tolerance; neither has been observed with β-NMN at dietary supplement doses up to 1,250 mg/day.

Populations Requiring Caution

No clinical contraindications have been identified for β-NMN at dietary supplement doses in the published literature. However, clinical data are absent or very limited for the following populations, and use should be discussed with a healthcare provider: pregnant or lactating women (no human safety data); individuals with chronic kidney disease (impaired metabolite clearance); individuals receiving PARP inhibitor chemotherapy (olaparib, rucaparib, niraparib — NAD+ augmentation may theoretically attenuate PARP inhibitor efficacy); individuals on CD38-targeting monoclonal antibodies (daratumumab); and individuals with active malignancy.

Known Drug Interactions

Drug class Potential interaction Management
PARP inhibitors (olaparib, rucaparib, niraparib) NAD+ augmentation may reduce inhibitor efficacy; theoretical based on mechanism Consult an oncologist before use; do not self-supplement
CD38 monoclonal antibodies (daratumumab) Shared NAD+ pathway; theoretical interaction Consult the prescriber before initiating NMN
Chemotherapy (general) NAD+ modulation may alter tumour-cell sensitivity; direction of effect is unclear Do not supplement without oncology guidance
Anticoagulants (warfarin) Potential interaction via vitamin K-related metabolic pathways; theoretical Monitor INR when initiating NMN supplementation

Regulatory Context & Quality

FDA Dietary Supplement Status: A Factual Disclosure

What Distinguishes High-Quality β-NMN

1. β-Anomer specificity. Only the β-NMN anomer is biologically active. Manufacturing processes that produce a mixture of α and β forms, or that fail to specify anomer purity, deliver reduced potency per milligram. A Certificate of Analysis should confirm ≥98% β-NMN by HPLC.

2. Stability controls. NMN is hygroscopic and susceptible to degradation with heat and moisture. Capsule formulations with appropriate desiccant packaging and stability-supporting excipients are essential. Open or inadequately sealed bulk powder formats are a quality risk.

3. Third-party analytical verification. An independent Certificate of Analysis (CoA) from an ISO 17025-accredited laboratory confirming identity, assay (β-NMN content vs. label claim), anomer purity, and absence of heavy metals, pesticide residues, and microbial contaminants.

4. Minimal excipient profile. A single-ingredient capsule should contain only the active compound and pharmaceutical-grade capsule components (e.g., HPMC for a vegetarian capsule). Unnecessary fillers and flow agents introduce variability and obscure label compliance.

Pacific Formulations Position

Pacific Formulations' Beta-NMN Capsules contain verified β-nicotinamide mononucleotide at a 500 mg dose calibrated to deliver meaningful NAD+ precursor supplementation within the range studied across human clinical trials. The single-ingredient capsule format eliminates confounders and allows users and their healthcare providers to assess individual response with precision — consistent with the standard expected by evidence-driven clinicians and informed consumers seeking clean, traceable supplementation.

Conclusion

β-Nicotinamide mononucleotide (NMN) has the most consistently replicated evidence base of any NAD+ precursor supplement for its primary biochemical action: reliably elevating circulating NAD+ and NAD+related metabolites in humans. This finding — dose-dependent from 250 mg to 900 mg per day, sustained over weeks to months, and reversed upon cessation — is confirmed across nine independent RCTs and corroborated by systematic review. Whether this biochemical target engagement translates into functional outcomes at dietary supplement doses remains the central open question in the field, and the honest answer is: selectively and modestly so, in certain populations.

The current human evidence supports the following positions: NAD+ elevation (strong evidence; consistent across all published trials); physical performance improvements such as gait speed and walking capacity (preliminary; positive signals in three RCTs, not confirmed in meta-analyses; not claimed); insulin sensitivity benefit in prediabetic postmenopausal women at 250 mg/day (moderate evidence in a narrow, specific population; not generalizable); modest diastolic blood pressure reduction (preliminary; one 2026 meta-analysis, 10 RCTs); and sleep quality improvement as secondary signals in two RCTs (preliminary; no primary-endpoint trial yet exists). Glycemic and lipid outcomes in healthy adults are null across meta-analyses totaling over 850 participants and are not claimed. Skeletal muscle mass and grip strength are not significantly affected in pooled analyses. The safety profile of β-NMN is excellent. No serious adverse events have been attributed to NMN in any published human trial at doses studied up to 1,250 mg/day. The FDA regulatory classification warrants disclosure, as provided in §6, but is a procedural determination that does not reflect a safety finding. Multiple registered clinical trials are currently recruiting, including trials addressing immunosenescence, renal function, and exercise tolerance, and the evidence base will continue to develop. Pacific Formulations presents this document as a working summary of the science as it currently stands — not a final verdict on a rapidly maturing field.

References

Sources

  1. Imai S. NAD World 3.0: the importance of the NMN transporter and eNAMPT in mammalian aging and longevity control. npj Aging. 2025. doi:10.1038/s41514-025-00192-6
  2. Li J, Yao Y, Niu X, Peng A, Xing J, Zhang K. The function of nicotinamide phosphoribosyl transferase (NAMPT) and its role in diseases. Front Mol Biosci. 2024;11:1480617. doi:10.3389/fmolb.2024.1480617
  3. Biological properties, synthetic pathways and anti-aging mechanisms of nicotinamide mononucleotide (NMN): research progress and challenges. Biogerontology. 2025. doi:10.1007/s10522-025-10270-7
  4. Okabe K, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Front Nutr. 2022;9:868640. doi:10.3389/fnut.2022.868640
  5. Lin J, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, dose-dependent clinical trial. GeroScience. 2022. doi:10.1007/s11357-022-00705-1. ClinicalTrials.gov: NCT04823260
  6. Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj Aging. 2022;8:11. doi:10.1038/s41514-022-00084-z. PMID: 35927255
  7. Morifuji M, et al. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults. GeroScience. 2024. doi:10.1007/s11357-024-01204-1. UMIN000047871
  8. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PMID: 33888596. ClinicalTrials.gov: NCT03151239
  9. Pencina MJ, et al. Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults: a physiologic study. J Clin Endocrinol Metab. 2023. PMID: 36740954
  10. Effects of nicotinamide mononucleotide supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2026. PMID: 41901064
  11. Kim M, et al. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults. Nutrients. 2022;14(4):755. doi:10.3390/nu14040755
  12. Effects of nicotinamide mononucleotide on glucose and lipid metabolism in adults: systematic review and meta-analysis. Curr Diabetes Rep. 2024. PMID: 39531138
  13. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism in adults: a systematic review and meta-analysis. 2024. PMID: 39116016
  14. Fukamizu Y, et al. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep. 2022;12:13922. doi:10.1038/s41598-022-18272-y
  15. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. 2026. PMID: 41655607
  16. Irie J, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2019. PMID: 31685720
  17. Yoshida M, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Nat Commun. 2017. PMC: 5668137 [Preclinical study; cited for mechanistic illustration only]
  18. Effects of nicotinamide mononucleotide supplementation on muscle and liver functions among the middle-aged and elderly: a systematic review and meta-analysis. 2024. PMID: 39185644
  19. The effect of nicotinamide mononucleotide and nicotinamide riboside on skeletal muscle mass and function: a systematic review and meta-analysis. 2025. PMID: 40275690
  20. Improved physical performance parameters in patients taking nicotinamide mononucleotide (NMN): a systematic review of randomized controlled trials. 2024. PMID: 39221308
  21. Katayoshi T, et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2023;13:2900. doi:10.1038/s41598-023-29787-3
  22. MIB-626, an oral formulation of a microcrystalline unique polymorph of β-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. Nutrients. 2022. PMID: 35182418

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This article is intended for informational and educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before beginning any supplementation program.

© 2026 Pacific Formulations. Prepared June 2026.

Tags: beta-nmn cellular energy healthy aging ingredient research white paper
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.